Galera Therapeutics, Inc. (GRTX)

Galera Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-59.08	-62.22	-87.73	-74.22	-51.93
Depreciation & Amortization	0.26	0.11	0.78	0.37	0.27
Share-Based Compensation	5.56	7.16	7.23	5.54	2.39
Other Operating Activities	8.42	11.52	11.76	8.78	2.61
Operating Cash Flow	-44.85	-43.43	-67.96	-59.54	-46.66
Capital Expenditures	-0.06	-0.03	-0.28	-0.46	-0.63
Acquisitions	-0.03	-0.02	-0.01	-0.04	0.03
Change in Investments	-72.64	-143.8	-149.48	-172.5	-219.19
Other Investing Activities	100.02	167.84	155.01	209.54	191.97
Investing Cash Flow	27.29	23.99	5.24	36.55	-27.83
Common Stock Issued	31.5	3.81	7.94	0.51	58.02
Other Financing Activities	-	0.08	58.77	20	20.01
Financing Cash Flow	31.5	3.89	66.71	20.51	78.03
Net Cash Flow	13.94	-15.54	3.99	-2.48	3.55
Free Cash Flow	-44.91	-43.45	-68.24	-59.99	-47.29
Free Cash Flow Per Share	-1.01	-1.60	-2.65	-2.41	-1.91

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.